Gimenez-Miranda, LuisBeltran-Romero, LuisLeon-Jimenez, DavidStiefel, Pablo2023-05-032023-05-032022-02-15Giménez-Miranda L, Beltrán-Romero L, León-Jimenez D, Stiefel P. PostCOVID effect on endothelial function in hypertensive patients: A new research opportunity. J Clin Hypertens (Greenwich). 2022 Feb;24(2):200-203.1524-6175http://hdl.handle.net/10668/19982SARS-CoV-2 is causing devastation both in human lives and economic resources. When the world seems to start overcoming the pandemics scourge, the threat of long-term complications of COVID-19 is rising. Reports show that some of these long-term effects may contribute to the main cause of morbimortality worldwide: the vascular diseases. Given the evidence of damage in the endothelial cells due to SARS-CoV-2 and that endothelial dysfunction precedes the development of arteriosclerosis, the authors propose to measure endothelial function around 6-12 months after acute disease in hypertensive patients, especially if they have other cardiovascular risk factors or overt vascular disease. The methods the authors propose are cost-effective and can be made available to any hypertension unit. These methods could be the "in vivo" assessment of endothelial function by flow mediated vasodilatation after ischemia by Laser-Doppler flowmetry and the measurement of plasma free circulating DNA and microparticles of endothelial origin.enAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/Laser-Doppler flowmetrySARS CoV-2circulating free DNAendothelial dysfunctionendothelial microparticlesCOVID-19Endothelial CellsEndothelium, VascularHumansHypertensionSARS-CoV-2Vasodilationresearch article34786820open accessSARS-CoV-2Enfermedades vascularesFlujometría por Láser-DopplerArteriosclerosisVasodilataciónIsquemiaHipertensiónPandemias10.1111/jch.143761751-7176PMC8646919https://doi.org/10.1111/jch.14376https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8646919/pdf